Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
PRO-P

Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative Outcome

Rekrutierend

NCT-Nummer:
NCT05644821

Studienbeginn:
August 2023

Letztes Update:
09.01.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Prostatic Neoplasms

Geschlecht:
Männer

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Heinrich-Heine University, Duesseldorf

Collaborator:
Marienhospital Herne, University Hospital, Essen, University Hospital, Bonn, Klinikum Dortmund gGbmH, University Hospital Muenster, University Hospital of Cologne, University of Cologne, Techniker Krankenkasse, Deutsche Krebsgesellschaft e.V.,

Studienleiter

Peter Albers, MD
Principal Investigator
University Clinic Düsseldorf, Urology
André Karger, MD
Study Director
University Clinic Düsseldorf, psychosomatic medicine

Kontakt

Dominik Fugmann, MD
Kontakt:
Phone: +49 (0)211-81 18 33 8
E-Mail: dominik.fugmann@med.uni-duesseldorf.de» Kontaktdaten anzeigen

Studienlocations
(3 von 5)

University Clinic Düsseldorf, Urology
40223 Düsseldorf
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Rouvier Al-Monajjed, MD
Phone: +49 0211 81 18110
E-Mail: urologie@med.uni-duesseldorf.de

Johanna Droop, PhD
Phone: +49 0211 81 19414
E-Mail: johanna.droop@med.uni-duesseldorf.de» Ansprechpartner anzeigen
University Clinik Bochum, Marienhospital Herne, Urology
44625 Herne
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Rein-Jüri Palisaar, MD
E-Mail: Rein-Jueri.Palisaar@elisabethgruppe.de

Meike Mohr
Phone: +49 02323 499- 1579
E-Mail: meike.mohr@elisabethgruppe.de» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

PRO-P is planned as a multicenter, prospective, and two-arm randomized control group study in

which ePROMs will be performed in a standardized fashion once before and six times

(intervention group) or three times (control group) after primary prostatectomy in patients

with PCa. PROMs are collected either web-based or through a dedicated app and entered by the

patient using either a mobile device or computer. Patients are invited to enter ePROMS into

the app or web tool through email and app-driven push messages. Patients who are incontinent

(at least one pad in 24 hours) at the 6-week postoperative survey are randomized into two

groups: The intervention group and the control group. In the intervention group, when the

respective questionnaire cut-off values are exceeded in the ePROM survey, an alarm is

triggered at the treating prostate cancer center and contact is made by the center as well as

subsequent measures, if necessary. This is done at 6 weeks postoperatively and at 12, 18, 24,

36 and 52 weeks postoperatively. In the control group, ePROMs are recorded 24 and 52 weeks

after radical prostatectomy, but without triggering an alarm with subsequent measures - the

control group thus receives treatment in accordance with the current clinical routine. The

mechanisms of action of the intervention will be investigated within the framework of a

qualitative process evaluation. Characteristics on the patient level (e.g., treatment-related

attitudes, comorbidity, social support), on the practitioner level (e.g., communication

skills), on the organizational level, and the interactions between the levels (e.g.,

patient-doctor relationship) will be explored. The goal is to develop an intervention model,

or to describe the effective elements of the intervention.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- age ≥ 18 y

- legal capacity

- sufficient knowledge of the German language

- prostate carcinoma, TNM T1-4 NX N0-1 M0-1c

- primary radical prostatectomy planned

- mobile input device or PC available

- ability to either receive emails or install a special app on cell phone and receive

push messages, with guidance or assistance if necessary

- ability to complete electronic questionnaires, with guidance or assistance if

necessary

Exclusion Criteria:

- palliative treatment situation (life expectancy < 1 year)

- preoperative urinary incontinence (at least one pad per 24 hours)

Studien-Rationale

Primary outcome:

1. urinary incontinence (Time Frame - 52 weeks):
The Expanded Prostate Cancer Index Short Form (EPIC-26) is a questionnaire that assesses symptoms and functions of people with prostate cancer in 5 domains. A total of 100 points can be achieved for each domain, with a higher score indicating better function. The urinary incontinence domain consists of four items. To calculate the primary endpoint, the difference between the scores on the urinary incontinence scale of the EPIC-26 is taken at 52 and 6 weeks. Changes regarding urinary incontinence (Minimally Important Difference (MID) >= 9) at 52 weeks postoperatively compared with 6 weeks postoperatively are considered.



Secondary outcome:

1. EPIC-26: changes in sexual function (Time Frame - 52 weeks):
Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in in sexual function according to EPIC-26 (MID >= 10).

2. EPIC-26: changes in irritative/obstructive symptoms (Time Frame - 52 weeks):
Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in irritative/obstructive an gastrointestinal symptoms according to EPIC-26 (MID >= 7).

3. EPIC-26: changes in gastrointestinal symptoms (Time Frame - 36 months):
Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes an gastrointestinal symptoms according to EPIC-26 (MID >= 5).

4. EPIC-26: changes in vitality/hormonal function (Time Frame - 52 weeks):
Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in vitality/ hormonal function according to EPIC-26 (MID >= 4).

5. EQ-5D-5L: changes in health-related quality of life (HRQoL) (Time Frame - 52 weeks):
The European Quality of Life Five-Dimensions Questionnaire (EQ-5D-5L) measures health-related quality of life on five scales: 1. mobility, 2. ability to care for oneself, 3. activities of daily living, 4. pain/physical discomfort, and 5. anxiety/dejection, each of which is represented by a question that provides five response options for grading symptoms. In addition, a question on self-assessment of health status is asked on a visual analog scale from 0 to 100, where 100 is the best imaginable health.

6. PHQ-4: changes in depressivity (Time Frame - 52 weeks):
The Patient Health Questionnaire-4 (PHQ-4) measures depressiveness and generalized anxiety on two subscales with two items each. For each question, scores from 0 to 3 can be achieved, so that a cumulative score of 12 points can be reached, whereby a higher score indicates a more pronounced symptomatology. The cut-off value for depressivity is defined for the subscales of the PHQ-4 is definied by >= 3 points, the respective attainment of which (independent of the preoperative value) triggers an alarm at each survey time point.

7. PHQ-4: changes in generalised anxiety (Time Frame - 52 weeks):
The Patient Health Questionnaire-4 (PHQ-4) measures depressiveness and generalized anxiety on two subscales with two items each. For each question, scores from 0 to 3 can be achieved, so that a cumulative score of 12 points can be reached, whereby a higher score indicates a more pronounced symptomatology. The cut-off value for depressivity is defined for the subscales of the PHQ-4 is definied by >= 3 points, the respective attainment of which (independent of the preoperative value) triggers an alarm at each survey time point.

8. PEI: changes in patient enablement (Time Frame - 52 weeks):
The Patient Enablement Instrument (PEI) measures patient empowerment through six questions; a validated German translation with a modified question sequence and Likert scale is used. Overall, the sum score ranges from 6 to 30 points, with a higher score corresponding to greater patient empowerment.

9. qualitative process evaluation - module 1: feasibility (Time Frame - 52 weeks):
semi-structured interviews with patients, urologists, psychooncologists, study nurses (N=10-15); data from Module 1 will be evaluated qualitatively using content analysis; criteria are based on the feasibility criteria for evaluating the acceptance and feasibility of the intervention and the study procedures

10. qualitative process evaluation - module 2: impact (Time Frame - 52 weeks):
sequential semi-structured interviews with patients and relatives from the intervention and control groups in the main study (N=30-40); data from module 2 will be evaluated by contrastive thematic coding; in addition to possible differences between the intervention and control groups, intraindividual changes are also evaluated by contrastive coding of the data material at several time points

11. qualitative process evaluation - module 3: implementation (Time Frame - 52 weeks):
Semi-structured interviews with urologists, psychooncologists, study nurses in the main study (N=10-15); focus group discussion with study participants; analysis of implementation factors is guided by the Consolidated Framework for Advancing Implementation Science (CFIR); data from module 3 on implementation are evaluated qualitatively by content analysis

Studien-Arme

  • Experimental: Intervention group
    Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the intervention group, when the respective questionnaire thresholds are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center, as well as subsequent actions, if necessary.
  • No Intervention: Control group
    Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the control group, ePROMs will be collected 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group will therefore receive treatment according to the current clinical routine.
  • Other: Comparison group
    In patients who are fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours), ePROMs are collected at 24 and 52 weeks, but no alarms or further actions are derived from them. Thus, treatment is provided according to routine clinical practice. Patients are not randomized.

Geprüfte Regime

  • complex intervention:
    The intervention has several elements: Regular symptom monitoring via ePROMs Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study, 4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist.
  • current clinical practice:
    current clinical practice

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative Outcome"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.